completed2023-11-01D series

Brolucizumab

Neubewertung nach Fristablauf: Neovaskuläre altersabhängige Makuladegeneration

Open official case page ↗

Brand: Beovu
Manufacturer: Novartis Pharma GmbH

G-BA action

final resolution

2024-07-09

Arzneimittel-Richtlinie/Anlage XII: Brolucizumab (Neovaskuläre altersabhängige Makuladegeneration) – Therapiekosten

Evidence-checked summary

The G-BA issued a final resolution on 2024-07-09. The official page states that it took effect as follows: 11.07.2024. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.

Open G-BA decision →Open official action source ↗

Final benefit result

G-BA result by patient group

Open decision 6578 →

Patient group

Erwachsene mit neovaskulärer (feuchter) altersabhängiger Makuladegeneration (AMD)

Added benefit not proven

Comparator
– Aflibercept oder Faricimab oder Ranibizumab

Open official result PDF ↗

Official case record

What happened, in source order

No inferred stages

Consultation record

Oral hearing and Wortprotokoll

1 hearing

2024-03-11

79 parsed turns

Oral hearing: Brolucizumab (Neubewertung nach Fristablauf: Neovaskuläre altersabhängige Makuladegeneration)

Official Wortprotokoll · 17 pages

Open official source PDF ↗Read transcript turns →

IQWiG comparison

Assessment record versus G-BA action

1 reference

IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.

A23-101

matched

Brolucizumab (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Official assessment PDF · 40 pages

Open structured assessment →Open official PDF ↗

G-BA decisions

Distinct actions and documents

2 decision

2024-05-02

final resolution

Arzneimittel-Richtlinie/Anlage XII: Brolucizumab (Neubewertung nach Fristablauf (Neovaskuläre altersabhängige Makuladegeneration))

The G-BA found no proven added benefit for Erwachsene mit neovaskulärer (feuchter) altersabhängiger Makuladegeneration (AMD). The appropriate comparator was – Aflibercept oder Faricimab oder Ranibizumab. The G-BA issued a final resolution on 2024-05-02. The official page states that it took effect as follows: 02.05.2024. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

4 official documents · 4 cited claims

Open decision →

2024-07-09

final resolution